A disease that affects less than 200,000 people in the United States at any given time is classified as a rare disease. There are over 6,800 rare diseases, according to the National Human Genome Research Institute. Approximately 80% of rare diseases are believed to have a genetic origin.
The stock we are revisiting today is that of Rezolute Inc. (RZLT), a late-stage rare disease company focused on developing transformative therapies for rare diseases with serious unmet needs. Its lead drug candidate is Ersodetug, under development for treating hypoglycemia (low blood sugar levels) due to any congenital or acquired form of Hyperinsulinism, say, Tumour-related HI.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com